Sustained-release naltrexone for alcoholism treatment: A preliminary study

Alcoholism: Clinical and Experimental Research

Volumn 22, Issue 5, 1998, Pages 1074-1079

  Kranzler, Henry R ^a   Modesto Lowe, Vania ^a   Nuwayser, Elie S ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b BIOTEK Inc   (United States)

Author keywords

Alcohol Dependence; Alcoholism; Naltrexone; Pharmacotherapy; Sustained Release Preparation

Indexed keywords

NALTREXONE;

ADULT; ALCOHOLISM; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SUSTAINED RELEASE PREPARATION;

EID: 0031715484     PISSN: 01456008     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1530-0277.1998.tb03703.x     Document Type: Article

References (28)

1. Volpicelli JR, Alterman AI, Hayashida M, O'Brien C: Naltrexone and the treatment of alcohol dependence. Arch Gen Psychiatry 49:876-880, 1992
2. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B: Naltrexone and coping skills therapy for alcohol dependence: A controlled study. Arch Gen Psychiatry 49:894-898, 1992
3. Kosten TR: Current pharmacotherapies of opioid dependence. Psychopharmacol Bull 26:69-74, 1990
4. Chick J: New insights in alcoholism treatment: The UK naltrexone study results. Presented at the Annual Meeting of the American Psychiatric Association, New York, May 5-9, 1996
5. Volpicelli J, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP: Naltrexone and alcohol dependence: Role of subject compliance. Arch Gen Psychiatry 54:737-742, 1997
6. Greenberg RN: Overview of patient compliance with medication dosing: A literature review. Clin Ther 6:592-599, 1984
7. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, James KE, Lacoursiere RB, Lee KK, Lowenstam I, Maany I, Neiderhiser D, Nocks JJ, Shaw S. Disulfiram treatment of alcoholism: A Veteran's Administration Cooperative Study. JAMA 256:1449-1455, 1986
8. Cox WM, Blount JP, Crowe PA, Singh SP: Diabetic patients' alcohol use and quality of life: Relationships with prescribed treatment compliance among older males. Alcohol Clin Exp Res 20:327-331, 1996
9. Johnson DAW: Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. J Clin Psychiatry 5:13-21, 1984
10. Chiang CN, Hollister LE, Kishimoto A, Barnett G: Kinetics of naltrexone sustained-release preparation. Clin Pharmacol Ther 36:704-708, 1984
11. Chiang CN, Hollister LE, Gillespie HK, Foltz RL: Clinical evaluation of a naltrexone sustained-release preparation. Drug Alcohol Depend 16:1-8, 1985
12. Heishman SJ, Francis-Wood A, Keenan RM, Chiang CN, Terrill JB, Tai B, et al.: Safety and pharmacokinetics of a new formulation of naltrexone, in Harris LS (ed): Problems of Drug Dependence 1993, vol 2, NIDA Research Monograph No. 141 (NIH Publ. No. 94-3749). Washington, D.C., U.S. Government Printing Office, 1994, p 82
13. Alim TN, Tai B, Chiang CN, Green T, Rosse RB, Lindquist T, et al.: Tolerability study of a depot form of naltrexone in substance abusers, in Harris LS (ed): Problems of Drug Dependence 1994, vol 2, NIDA Research Monograph No. 153 (NIH Publ. No. 95-3883). Washington, D.C., U.S. Government Printing Office, 1995, p 253
14. Marlatt GA, Gordon JR: Relapse Prevention. New York, Guilford, 1985
15. Chaney EF: Social skills training, in Hester RK, Miller WR (eds): Handbook of Alcoholism Treatment Approaches: Effective Alternatives. New York, Pergamon Press, 1989
16. Selzer ML: The Michigan Alcoholism Screening Test: The quest for a new diagnostic instrument. Am J Psychiatry 127:1653-1658, 1971
17. McLellan AT, Luborsky L, Cacciola J, Griffith J, McGahan P, O'Brien CP: Guide to the Addiction Severity Index: Background, Administration, and Field Testing Results. U.S. DHHS Publication No. (ADM) 88-1419. Washington, D.C., U.S. Government Printing Office, 1988
18. Skinner H, Allen BA: Alcohol dependence syndrome: Measurement and validation. J Abnorm Psychol 91:199-209, 1982
19. Sobell MB, Maisto SA, Sobell LC, Cooper AM, Cooper TC, Sanders TB: Developing a prototype for evaluating alcohol treatment effectiveness, in Sobell LC, Sobell MB, Ward E (eds): Evaluating Alcohol and Drug Abuse Treatment Effectiveness: Recent Advances. New York, Pergamon Press, 1980
20. Levine J, Schooler NR: SAFTEE: A technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 22:343-381, 1986
21. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 4:461-471, 1961
22. Biometrics Research Department, NY State Psychiatric Institute: Structured Clinical Interview for DSM-IV (SCID-I). New York, NY State Psychiatric Institute, 1995
23. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, D.C., American Psychiatric Press, 1994
24. Huang W, Moody DE, Foltz RL, Walsh SL: Determination of naltrexone and 6-β-naltrexol in plasma by solid-phase extraction and gas chromatography-negative ion chemical ionization-mass spectrometry. J Anal Toxicol 21:252-257, 1997
25. Verebey K, Volavka J, Mule SJ, Resnick RB: Naltrexone: Disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther 20:315-328, 1976
26. Cohen J: Statistical Power for the Behavioral Sciences, ed 2. Hillsdale, NJ, Lawrence Erlbaum Associates, Inc., 1988
27. Kranzler HR, Mason BJ, Pettinati HM, Anton RF: Methodological issues in pharmacotherapy trials with alcoholics, in Hertzman M, Feltner D (eds): The Handbook of Psychopharmacology Trials. New York, New York University Press, 1997, pp 213-245
28. Olsen JL, Kind FA: A review of parenteral sustained-release naltrexone systems, in Narcotic Antagonists: Naltrexone Pharmacochemistry and Sustained-Release Preparations, NIDA Monograph Series #28. DHHS Publ. No. (ADM) 81-102. Washington, D.C., U.S. Government Printing Office, 1981, pp 187-193